Skip to main content

Market Overview

OptimizeRx Snags Equity Capital Raise of $65.6M

  • OptimizeRx Corporation (NASDAQ: OPRXprices its previously announced underwritten public offering of 1.325 million common shares, at $49.50 per share, raising $65.6 million in gross proceeds.
  • Underwriters have an option to purchase up to an additional 198,750 shares. The offering is expected to close by February 11.
  • The offer price represents a marginal discount of 4% on the last close price of $51.76 on Monday.
  • OPRX will use the net proceeds for general corporate purposes, including future acquisitions.
  • William Blair & Company and RBC Capital Markets are acting as joint book-running managers for the offering. 
  • OptimizeRx is firing on all cylinders, in part because the COVID-19 pandemic has made access to doctors even more difficult for sales reps. The company reported 117% revenue growth in its fourth quarter and forecasted positive net income. The company expects revenue of approximately $43 million for the full year, up 75% over 2019. The company has $170 million worth of sales in the pipeline and reports seeing a shift to recurring revenue streams from its pharmaceutical partners.
  • Price Action: OPRX shares reached 5.9% higher at $54.76 during the market trading session on the last check Tuesday.

Related Articles (OPRX)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News Offerings Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at